Literature DB >> 33707751

FDA approves first anti-ANGPTL3 antibody, for rare cardiovascular indication.

Asher Mullard.   

Abstract

Entities:  

Year:  2021        PMID： 33707751     DOI： 10.1038/d41573-021-00047-1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.

Authors:  Tom G Richardson; Genevieve M Leyden; Qin Wang; Joshua A Bell; Benjamin Elsworth; George Davey Smith; Michael V Holmes
Journal:  PLoS Biol       Date:  2022-02-25       Impact factor: 8.029

Review 2.  Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.

Authors:  Pei-Yi Chen; Wan-Yun Gao; Je-Wen Liou; Ching-Yen Lin; Ming-Jiuan Wu; Jui-Hung Yen
Journal:  Int J Mol Sci       Date:  2021-07-07       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.